Leucine-Rich Repeat Kinase 2 Colocalizes with α-Synuclein in Parkinson’s Disease, but Not Tau-Containing Deposits in Tauopathies

George Perry; Xiongwei Zhu; Asim K. Babar; Sandra L. Siedlak; Qiwei Yang; Genta Ito; Takeshi Iwatsubo; Mark A. Smith; Shu G. Chen

doi:10.1159/000113708

Related publications

Article2006

LRRK2 in Parkinson's disease and dementia with Lewy bodies.

Xiongwei Zhu, Asim K. Babar, Sandra L. Siedlak, Qiwei Yang, Genta Ito, Takeshi Iwatsubo, Mark A. Smith, George Perry, Shu G. Chen

Article2006

P4–162: LRRK2 in Lewy bodies of Parkinson's disease and dementia with Lewy bodies

Mark A. Smith, Xiongwei Zhu, Asim K. Babar, Sandra L. Siedlak, Qiwei Yang, Genta Ito, Takeshi Iwatsubo, George Perry, Shu G. Chen

Article2020

Metabolic alterations in plasma from patients with familial and idiopathic Parkinson’s disease

Sokhna M. S. Yakhine-Diop, José Á. Morales-García, Mireia Niso‐Santano, Rosa A. González‐Polo, Elisabet Uribe-Carretero, Guadalupe Martínez-Chacón, Sylvère Durand, Maria Chiara Maiuri, Ana Aiastui, Miren Zulaica, Javier Ruiz‐Martínez, Adolfo López de Munaín, Jordi Pérez‐Tur, Ana Pérez‐Castillo, Guido Guido Kroemer, José Manuel Bravo‐San Pedro, José M. Fuentes

Article2006

α‐Synuclein facilitates the toxicity of oxidized catechol metabolites: Implications for selective neurodegeneration in Parkinson's disease

Takafumi Hasegawa, Michiko Matsuzaki‐Kobayashi, Atsushi Takeda, Naoto Sugeno, Akio Kikuchi, Katsutoshi Furukawa, George Perry, Mark A. Smith, Yasuto Itoyama

Article2022

The Parkinson’s disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability

Erinc Hallacli, Can Kayatekin, Sumaiya Nazeen, Xiou H. Wang, Zoe Sheinkopf, Shubhangi Sathyakumar, Souvarish Sarkar, Xin Jiang, Xianjun Dong, Roberto Di Maio, Wen Wang, Matthew T. Keeney, Daniel Felsky, Jackson Sandoe, Aazam Vahdatshoar, Namrata D. Udeshi, D.R. Mani, Steven A. Carr, Susan Lindquist, Philip L. De Jager, David Bartel, Chad L. Myers, J. Timothy Greenamyre, ,

Leucine-Rich Repeat Kinase 2 Colocalizes with α-Synuclein in Parkinson’s Disease, but Not Tau-Containing Deposits in Tauopathies

Abstract

Discussion(0)

Related publications

LRRK2 in Parkinson's disease and dementia with Lewy bodies.

P4–162: LRRK2 in Lewy bodies of Parkinson's disease and dementia with Lewy bodies

Metabolic alterations in plasma from patients with familial and idiopathic Parkinson’s disease

α‐Synuclein facilitates the toxicity of oxidized catechol metabolites: Implications for selective neurodegeneration in Parkinson's disease

The Parkinson’s disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability